Over the years, I have heard from many patients who wanted to learn about the Trifecta heart valve replacement and its clinical trials. As you might recall, this aortic valve replacement device is described by St. Jude Medical, its manufacturer, as a “next generation” heart valve replacement that:
- Contains three pericardial tissue leaflets;
- Uses a titanium stent covered with polyester and pericardial tissue; and
- Leverages St. Jude’s patented Linx AC Technology to help prevent aortic valve calcification after implant.

Trifecta Heart Valve Replacement (St. Jude Medical)
Recently, there was big news for the Trifecta heart valve replacement when St. Jude announced that this device received FDA approval.
The corporate excitement for the FDA approval was more than apparent when I checked into the Marriott hotel the night before the 91st Annual American Association for Thoracic Surgeons meeting began in Philadelphia. To my surprise… When I looked down at my room key, this is what I saw:

My Trifecta Hotel Room Key During AATS At The Marriott
I’m a little slow at times. I don’t always know when product marketing is happening to me or those around me. But, in that moment, I started to think that the marketing organization at St. Jude Medical was going to use the AATS convention as a launching pad for the Trifecta heart valve replacement. I guess that’s a very appropriate strategy — considering 1,500+ cardiac surgeons attend the AATS meeting each year.
Interestingly, the next morning…
Read the rest of this entry »